Alterity Therapeutics Files 6-K on Substantial Holding Change
Ticker: PRNAF · Form: 6-K · Filed: Sep 17, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: substantial-holding, 6-k, registration-statement
Related Tickers: ATHE
TL;DR
ALTERITY THERAPEUTICS LTD (ATHE) filed a 6-K for a substantial holding change - watch for ownership shifts.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on September 17, 2025, to report a change in substantial holding. This filing is incorporated by reference into several of Alterity's registration statements on Forms S-8 and F-3. The company, formerly known as Prana Biotechnology Ltd, is a development stage enterprise based in Melbourne, Australia.
Why It Matters
This filing indicates a significant shift in ownership structure, which could impact the company's stock performance and strategic direction.
Risk Assessment
Risk Level: medium — Filings related to substantial holding changes can signal shifts in investor confidence or strategic maneuvering, warranting closer attention.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- Prana Biotechnology Ltd (company) — Former company name
- September 17, 2025 (date) — Filing date
- Form S-8 (document) — Incorporated by reference
- Form F-3 (document) — Incorporated by reference
FAQ
What specific event triggered this Form 6-K filing?
The filing is specifically to report a 'Change in substantial holding'.
When was this Form 6-K filed?
The Form 6-K was filed on September 17, 2025.
What is the principal executive office address for Alterity Therapeutics Limited?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Is Alterity Therapeutics Limited required to file annual reports under Form 20-F or Form 40-F?
Yes, the registrant indicates it files annual reports under cover of Form 20-F.
What other registration statements is this 6-K filing being incorporated into?
This 6-K is incorporated by reference into Alterity's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
Filing Stats: 188 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2025-09-17 08:00:13
Filing Documents
- ea0257681-6k_alterity.htm (6-K) — 14KB
- ea025768101ex99-1_alterity.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 507KB
- ex99-1_002.jpg (GRAPHIC) — 271KB
- ex99-1_003.jpg (GRAPHIC) — 253KB
- ex99-1_004.jpg (GRAPHIC) — 239KB
- ex99-1_005.jpg (GRAPHIC) — 489KB
- ex99-1_006.jpg (GRAPHIC) — 287KB
- 0001213900-25-088363.txt ( ) — 2845KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Change in substantial holding 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: September 17, 2025 2